Top member reports
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Investor Presentation - Quarte
stale
FDA on PXS - 5505 myelofibrosis ongoing study
The science in the charts below
#FDA Review PXS Accelerates Pla
stale
Phase 2 clinical trial of PXS‐5505 in myelofibrosis (MF). Following helpful feedback from the U.S. Food and Drug Administration (FDA), the trial will be widened to include myelofibrosis patients already receiving a JAK inhibitor as standard of care in combination with PXS‐5505
